Humanigen says its antibody reduced need for ventilation in COVID-19 patients by 54%

COVID-19 patients who received Humanigen's monoclonal antibody lenzilumab were 54 percent more likely to survive without needing ventilation over a 28-day period compared to patients who received a placebo, the drugmaker announced March 29.